- Home
- AKBA vs ESEA Comparison
AKBA vs ESEA Comparison
Compare AKBA & ESEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- ESEA
- Stock Information
- Founded
- AKBA 2007
- ESEA 2005
- Country
- AKBA United States
- ESEA Greece
- Employees
- AKBA N/A
- ESEA N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- ESEA Marine Transportation
- Sector
- AKBA Health Care
- ESEA Consumer Discretionary
- Exchange
- AKBA Nasdaq
- ESEA Nasdaq
- Market Cap
- AKBA 336.2M
- ESEA 253.9M
- IPO Year
- AKBA 2014
- ESEA 2006
- Fundamental
- Price
- AKBA $2.13
- ESEA $34.13
- Analyst Decision
- AKBA Strong Buy
- ESEA Buy
- Analyst Count
- AKBA 1
- ESEA 1
- Target Price
- AKBA $7.50
- ESEA $53.00
- AVG Volume (30 Days)
- AKBA 2.3M
- ESEA 38.2K
- Earning Date
- AKBA 03-13-2025
- ESEA 02-24-2025
- Dividend Yield
- AKBA N/A
- ESEA 7.03%
- EPS Growth
- AKBA N/A
- ESEA 3.12
- EPS
- AKBA N/A
- ESEA 16.28
- Revenue
- AKBA $169,879,000.00
- ESEA $208,648,067.00
- Revenue This Year
- AKBA N/A
- ESEA $13.72
- Revenue Next Year
- AKBA $19.31
- ESEA $3.06
- P/E Ratio
- AKBA N/A
- ESEA $2.10
- Revenue Growth
- AKBA N/A
- ESEA 13.90
- 52 Week Low
- AKBA $0.80
- ESEA $30.21
- 52 Week High
- AKBA $2.48
- ESEA $50.92
- Technical
- Relative Strength Index (RSI)
- AKBA 51.56
- ESEA 54.27
- Support Level
- AKBA $2.07
- ESEA $33.51
- Resistance Level
- AKBA $2.22
- ESEA $35.86
- Average True Range (ATR)
- AKBA 0.07
- ESEA 1.15
- MACD
- AKBA -0.02
- ESEA 0.46
- Stochastic Oscillator
- AKBA 21.43
- ESEA 69.38
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.